Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells

British Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 855-861

  Sherwood, E R ^a   Van Dongen, J L ^a   Wood, C G ^a   Liao, S ^b   Kozlowski, J M ^a   Lee, C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Androgen; Epidermal growth factor receptors; Prostate cancer

Indexed keywords

ANDROGEN; ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN PHOSPHORYLATION;

EID: 0031937611     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.142     Document Type: Article

References (37)

1. Aaronson S (1991) Growth factors and cancer. Science 254: 1146-1153
2. Brass A, Barnard J, Patai B, Salvi D and Rukstalis D (1995) Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 55: 3197-3203
3. Butler WWS and Schade AL (1958) The effect of castration and androgen replacement on the nucleic acid composition and enzymatic capacity of the rat prostate. Endocrinology 63: 271-279
4. Ching K, Ramsey E, Pettigrew M, D'Cunha R, Jason M and Dodd J (1993) Expression of mRNA for epidermal growth factor and transforming growth factor alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126: 151-158
5. Connolly J and Rose D (1990) Production of epidermal growth factor and transforming growth factor alpha by the androgen responsive LNCaP human prostate cancer cell line. Prostate 16: 209-218
6. Connolly J and Rose D (1991) Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor related peptides. Prostate 19: 173-180
7. Damber J, Bergh A, Assarsson B and Gafvels M (1995) Epidermal growth factor receptor content in rat prostatic carcinoma: effects of endocrine treatment. Urol Res 23: 119-125
8. Davies P and Eaton C (1989) Binding of epidermal growth factor by human normal, hypertrophic and carcinomatous prostate. Prostate 14: 123-132
9. Deneshagari F and Crawford ED (1993) Endocrine therapy of advanced carcinoma of the prostate. Cancer 71: 1089-1097
10. Fong C, Sherwood E, Mendelsohn J, Lee C and Kozlowski J (1992) Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 52: 5887-5892
11. Geller J, Albert J and Vik A (1988) Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin in Oncol 15: 53-61
12. Gill G, Kawamoto T, Cochet C, Le A, Sato J, Masui H, McLeod C and Mendelsohn J (1984) Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7766
13. Glynn-Jones E, Goddard L and Harper M (1996) Comparative analysis of mRNA and protein expression for EGFR and ligands: relationship to proliferative index in human prostate tissue. Human Pathol 27: 688-696
14. Hofer D, Sherwood E, Bromberg W, Mendelsohn J, Lee C and Kozlowski J (1991) Autonomous growth of androgen independent prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780-2785
15. Huggins C and Hodges CV (1941) Studies on prostate cancer. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297
16. Ibrahim G, Kerns B, MacDonald J, Ibrahim S, Kinney R, Humphrey P and Robertson C (1993) Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149: 170-173
17. Isaacs JT (1984) Antagonistic effect of androgen on prostatic cell death. Prostate 5: 545-557
18. Jarrard D, Blitz B, Smith R, Patai B and Rukstalis D (1994) Effect of epidermal growth factor on prostate cancer cell line PC3 growth and metastasis. Prostate 26: 46-53
19. Kaplan P, Leav I, Greenwood J, Kwan P and Ho S (1996) Involvement of transforming growth factor alpha and epidermal growth factor receptor in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. Carcinogenesis 17: 2571-2579
20. Kawamoto T, Sato J, Le A, Sato A, Polikoff J and Mendelsohn J (1983) Growth stimulation of A431 cells: identification of high affinity receptors by antireceptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337-1341
21. Kozlowski J, McEwan R, Keer H, Sensibar J, Sherwood E, Lee C, Grayhack J, Albini A and Martin G (1988) Prostate cancer and the invasive phenotype: application of new in vivo and in vitro approaches. In Tumor Growth and Metastasis. Fidler IJ and Nicholson G. (eds), pp. 189-231, Alan R, Liss: New York
22. Lee C and Sensibar J (1978) Proteins of the rat prostate. II. Synthesis of new proteins in the ventral lobe during castration-induced regression. J Urol 138: 903-908
23. Leevers S, Patterson H and Marshall C (1994) Requirement for ras in raf activation is overcome by targeting raf to the plasma membrane. Nature 369: 411-414
24. Lepor H, Ross A and Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostate cancer. J Urol 128: 335-340
25. Liu X, Wiley H and Meikle A (1993) Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor alpha and epidermal growth factor/TGFα receptor. J Clin Endocrinol Metab 77: 1472-1478
26. Maygarden S, Strom S and Ware J (1992) Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia and benign hyperplasia. Arch Pathol Lab Med 116: 269-273
27. McDonald A and Habib F (1992) Divergent responses of epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 65: 177-182
28. Mellon K, Thompson S, Charlton R, Marsh C, Robinson M, Lane D, Harris A, Home C and Neal D (1992) p53, c-erbb-2 and epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496-499
29. Montone E and Tomaszewski J (1993) In situ hybridization of epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma. J Clin Lab Anal 7: 188-195
30. Morris G and Dodd J (1990) Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143: 1272-1274
31. Pellicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T and Pellicci P (1992) A novel transforming protein (Shc) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93-104
32. Schuurmans A, Bolt J, Voorhorst M, Blankenstein R and Mulder E (1988) Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer 42: 917-922
33. Scott WW. Menon M and Walsh PC (1980) Hormonal therapy of prostate cancer. Cancer 45: 1924-1936
34. Sherwood E, Berg L, McEwan R, Pasciak R, Kozlowski J and Lee C (1989) Two-dimensional protein profiles of cultured stromal and epithelial cells from hyperplastic human prostate. J Cell Biochem 40: 201-214
35. Turner T, Chen P, Goodly L and Wells A (1996) EGF receptor signaling enhances in vivo invasiveness of DU145 human prostate carcinoma cells. Clin Exp Metastasis 14: 409-418
36. Visacorpi T, Kallioniami O, Koivula T, Harvey J and Isola J (1992) Expression of EGFR and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Modern Pathol 5: 643-648
37. Wilding G, Valverius E, Knabbe C and Gelmann E (1989) Role of transforming growth factor alpha in human prostate cancer growth. Prostate 15: 1-12